סובוקסון 2 מ"ג/ 0.5 מ"ג - Suboxone 2 mg/0.5 mg
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× |
| |||||
|---|---|---|---|---|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | N02AE Oripavine derivatives | |||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| |||||
| צ×רת ××ª× | פ××× - PER OS | |||||
| צ×רת ××× ×× | ×××××ת ×××ª× ×ת×ת ××ש××, TABLETS SUBLINGUAL ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | |||||
| ×ת×××× | Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse.Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction.
| |||||
× ×ª×× × ×¡× [ ×צ×× ]
| ||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | |||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ס×××קס×× 2 ×"×/ 0.5 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | INDIVIOR UK LIMITED, UK |
| ×©× ××¢× ×ר×ש×× | NAOMI SHACO-EZRA LTD |
| ר×ש××× | ת×ר×× ××ש×: 06/2012. ר×ש××× ×ת×ר××: 03/2018 |
| ת×ר×× ×¢×××× ××ר×× | 15/05/19 |
ת××× ×ª ×ר×××